{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":17,"n_cols":5,"rows_kept":17,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910985626203321"]
[null,null,"Autore",null,"Kumar Dileep"]
[null,null,"Titolo",null,"Enzymatic Targets for Drug Discovery Against Alzheimer's Disease"]
[null,null,"Pubbl/distr/stampa",null,"Sharjah : , : Bentham Science Publishers, , 2023"]
[{"$nulls":4},"©2023"]
[null,null,"ISBN",null,"9789815136142"]
[{"$nulls":4},"9815136143"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (289 pages)"]
[null,null,"Soggetti",null,"Alzheimer's disease"]
[{"$nulls":4},"Drug development"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Recent Advances In Tacrine-Based Anti-Alzheimer’s Drug Design  --   Atukuri Dorababu1,* --   INTRODUCTION --     Multi-Target Anti-Alzheimer’s Agents --       Tacrine-Heterocycle Hybrids --       Tacrine - Non-Heterocycle Hybrids --     Cholinesterase Inhibitors --       Tacrine-Heterocycle Based ChE Inhibitors --       Tacrine-Non-Heterocycle-Based Derivatives --   DISCUSSION AND CONCLUSION --   REFERENCES -- Epigenetics of Alzheimer’s Disease: Past, Present and Future  --   Divya Adiga1, Sangavi Eswaran1, S. Sriharikrishnaa1, Nadeem G. Khan1, Shama Prasada Kabekkodu1,* and Dileep Kumar2,3 --   INTRODUCTION --     Alzheimer’s Disease (AD) --   ROLE OF EPIGENETIC MODIFICATIONS IN AD --     DNA Methylation --     Hydroxy-Methylation --     Mitochondrial DNA Methylation --     Histone Modifications --     Non Coding RNAs (ncRNAs) --       Long-Non Coding RNAs (LncRNAs) in AD Pathogenesis"]
[null,null,null,"Sommario/riassunto","The book summarizes the role of multiple enzyme targets and strategies to design and develop novel drug candidates for Alzheimer's disease (AD). It brings together researchers across the globe having varied scientific backgrounds and expertise in a single volume.The chapters highlight current information scientists have unraveled about the origin, pathogenesis and prevention of AD. The contributions consider both established and emerging drug targets viz. Tau proteins, TREM, and microglia. Topics covered in the book include multi-target "]
[{"$nulls":4},"anti-Alzheimer's agents, epigenetic modifications, and the role of specific proteins like TMP21 and Tau in AD. A section dedicated to pharmacological treatments discusses the significance of tubulin-modifying enzymes, memantine, and glutamate antagonists. Enzymatic targets for drug discovery are thoroughly examined, focusing on cholinesterase, secretases, and other enzymes. Additionally, the book explores innovative nano-carrier-based drug delivery methods, emphasizing the crucial role of nanotechnology in effective Alzheimer's treatment. The book aims to inform students and researchers in the field of neuroscience, medicine and pharmacology about current research and biochemical nuances of AD pathogenesis and enzymatic drug targeting strategies. Readership Students and researchers in the field of neuroscience, medicine and pharmacology."]